Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
Rhea-AI Summary
Aardvark Therapeutics (Nasdaq: AARD) has voluntarily paused the Phase 3 HERO trial (NCT06828861) and its open-label extension (NCT07197034) for ARD-101 in Prader-Willi syndrome due to reversible cardiac observations at above-target doses observed in a healthy volunteer study.
The company paused enrollment and dosing while conducting a comprehensive data review, will collaborate with the FDA and experts, and now expects to delay topline HERO data previously planned for Q3 2026, with further guidance expected in Q2 2026.
Positive
- Voluntary pause prioritizes patient safety while data are reviewed
- Company will collaborate with FDA and clinical experts during review
- Management committed to evaluating optimal therapeutic dosing to support program progress
Negative
- Enrollment and dosing in the Phase 3 HERO trial and open-label extension are paused
- Topline HERO trial data no longer expected in Q3 2026
- Safety observations at above-target doses in healthy volunteers prompted the program interruption
News Market Reaction – AARD
On the day this news was published, AARD declined 56.20%, reflecting a significant negative market reaction. Argus tracked a trough of -21.9% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $349M from the company's valuation, bringing the market cap to $272M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Ahead of this news, AARD was up 0.97% while peers showed mixed, modest moves (e.g., CABA -0.57%, NVCT -0.56%, KYTX +0.37%, NTHI +0.20%), indicating stock-specific risk rather than a sector rotation.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Protocol amendment approved | Positive | -6.5% | IRB approval and FDA submission to lower minimum age to 7 years. |
| Dec 10 | First patient dosed | Positive | +11.7% | First HERO patient dosed in Australia and multi-country enrollment progress. |
| Oct 08 | FDA protocol alignment | Positive | -1.6% | FDA alignment on protocol amendment expanding HERO trial population age range. |
Clinical-trial updates for ARD-101 have produced mixed reactions, with one strong positive move and two negative moves, suggesting investors respond sharply to perceived changes in trial momentum or population scope.
Over the past few quarters, Aardvark has consistently highlighted progress in the Phase 3 HERO trial for ARD-101 in Prader-Willi syndrome. Events included FDA alignment on protocol amendments in Oct 2025, first patient dosing in Australia in Dec 2025, and IRB approval plus FDA submission of an amended protocol in Feb 2026. Those updates generally expanded eligibility and affirmed a Q3 2026 topline goal, whereas today’s announcement introduces a pause and timeline uncertainty.
Historical Comparison
Prior ARD-101 clinical-trial releases produced moves from -6.45% to +11.66%, averaging 1.2%. Those focused on enrollment expansion and regulatory alignment, whereas the current voluntary Phase 3 pause introduces new safety uncertainty.
Clinical communications have tracked HERO’s evolution: FDA protocol alignment, then multi-country enrollment and age expansion to younger patients. The new pause interrupts that trajectory by reassessing safety at higher ARD-101 doses and delaying the previously targeted Q3 2026 topline readout.
Market Pulse Summary
The stock dropped -56.2% in the session following this news. A negative reaction despite prior optimism about HERO’s progress would fit the pattern of sharp responses to ARD-101 news, including moves of -6.45% after earlier protocol updates. The voluntary pause, cardiac safety signal at higher doses, and loss of the Q3 2026 topline goal add material program risk. Past insider purchases and existing cash provide context but do not mitigate the need for a clear safety path forward.
Key Terms
phase 3 medical
randomized, double-blind, placebo-controlled medical
open-label extension medical
hyperphagia medical
prader-willi syndrome medical
institutional review board regulatory
topline data technical
AI-generated analysis. Not financial advice.
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS).
The decision by Aardvark to voluntarily pause the HERO (NCT06828861) and open-label extension (NCT07197034) trials was based on reversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study. Aardvark is conducting a comprehensive review of the data to inform next steps. Out of an abundance of caution, the company has voluntarily paused ongoing enrollment and dosing in the HERO trial during this evaluation.
“The safety of every patient in our clinical studies is our highest priority, so we will thoroughly evaluate the signals seen at higher than therapeutic doses of ARD-101 in a healthy volunteer study,” said Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark. “We are committed to advancing the ARD-101 clinical program and we are evaluating optimal therapeutic dosing levels to support its progress. We will continue to collaborate closely with the FDA and scientific and clinical experts, and we greatly appreciate our partnership with the PWS community as we determine next steps for this program.”
Based on the ongoing activities in the ARD-101 program, Aardvark no longer anticipates announcing topline data from the HERO trial in the third quarter of 2026 and expects to provide further guidance in the second quarter of this year.
About ARD-101
ARD-101 is a gut-restricted small molecule agonist of select taste receptors (TAS2Rs) expressed on the luminal side of the intestine. As a potent bitter taste receptor pan-agonist, ARD-101 stimulates enteroendocrine cells of the digestive tract to release multiple gut-peptide hormones, including GLP-1 and the satiety hormone cholecystokinin (CCK), which activates gut-brain neurologic signaling to mediate hunger. ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies. The FDA has granted ARD-101 both Orphan Drug Designation and Rare Pediatric Disease Designation for Prader-Willi Syndrome (PWS).
About Aardvark Therapeutics, Inc.
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases. Hunger, which is the discomfort from not having eaten recently, is a distinct neural signaling pathway separate from appetite, the reward-seeking desire for food. Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. Our lead compound, oral ARD-101, is in Phase 3 clinical development for the treatment of hyperphagia associated with PWS, a rare disease characterized by insatiable hunger. Aardvark is also developing ARD-201, a planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor, through two separate Phase 2 trials with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for obesity and obesity-related conditions. For more information, visit www.aardvarktherapeutics.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning: Aardvark’s business strategy, product candidates, ongoing clinical trials, planned clinical trials, expected timing for data readouts and reporting interim, preliminary or topline results, likelihood of success, as well as plans and objectives of management for future operations. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include statements regarding ARD-101, including the review of the data from the healthy volunteer study, the expected timeline for announcing topline data from the Phase 3 HERO trial, potential next steps for ARD-101, and Aardvark’s expected timing for providing further guidance. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to potential delays in the commencement, enrollment and completion of clinical trials; the risk that Aardvark may use its capital resources sooner than expected and that they may be insufficient to allow Aardvark to achieve its anticipated milestones; risks related to its dependence on third parties for manufacturing, shipping and production of drug product for use in clinical trials and preclinical studies; the risk of unfavorable clinical trial results; the risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results; and other risks and uncertainties, including the factors described under the “Risk Factors” section of Aardvark’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 that Aardvark filed with the Securities and Exchange Commission on November 13, 2025. When evaluating Aardvark’s business and prospects, careful consideration should be given to these risks and uncertainties. Any forward-looking statements contained in this press release are based on the current expectations of Aardvark’s management team and speak only as of the date hereof, and Aardvark specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.
Investor Contact:
Courtney Mogerley
Argot Partners
(212) 600-1902
Aardvark@Argotpartners.com
Media Contact:
Andrea Cohen
Sam Brown LLC
(917) 209-7163
Andreacohen@Sambrown.com
FAQ
Why did Aardvark (AARD) pause the Phase 3 HERO trial on February 27, 2026?
What parts of the ARD-101 program did Aardvark (AARD) pause on Feb 27, 2026?
How does the HERO trial pause affect Aardvark's (AARD) topline data timeline?
Will Aardvark (AARD) work with regulators after pausing the HERO trial?
Are the cardiac observations from ARD-101 reported as permanent or reversible?
